Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.

Dimitrova D, Gea-Banacloche J, Steinberg SM, Sadler JL, Hicks SN, Carroll E, Wilder JS, Parta M, Skeffington L, Hughes TE, Blau JE, Broadney MM, Rose JJ, Hsu AP, Fletcher R, Nunes NS, Yan XY, Telford WG, Kapoor V, Cohen JI, Freeman AF, Garabedian E, Holland SM, Lisco A, Malech HL, Notarangelo LD, Sereti I, Shah NN, Uzel G, Zerbe CS, Fowler DH, Gress RE, Kanakry CG, Kanakry JA.

Biol Blood Marrow Transplant. 2019 Sep 4. pii: S1083-8791(19)30558-0. doi: 10.1016/j.bbmt.2019.08.018. [Epub ahead of print]

PMID:
31493539
2.

Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.

Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG.

J Clin Invest. 2019 Mar 26;129(6):2357-2373. doi: 10.1172/JCI124218.

3.

Differential Cytokine Utilization and Tissue Tropism Results in Distinct Repopulation Kinetics of Naïve vs. Memory T Cells in Mice.

Kim HK, Chung H, Kwon J, Castro E, Johns C, Hawk NV, Hwang S, Park JH, Gress RE.

Front Immunol. 2019 Mar 4;10:355. doi: 10.3389/fimmu.2019.00355. eCollection 2019.

4.

Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):577-586. doi: 10.1016/j.bbmt.2018.10.011. Epub 2018 Oct 18.

PMID:
30342913
5.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Kerep AZ, Broome J, Pirsl F, Curtis LM, Steinberg SM, Mitchell SA, Cowen EW, Pichard DC, Joe GO, Comis LE, Mays JW, Datiles MB 3rd, Stratton P, Zolton J, Berger A, Hendricks J, Kenyon M, Baruffaldi J, Titarenko I, Pulanic D, Baird K, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2019 Jan;54(1):76-84. doi: 10.1038/s41409-018-0224-3. Epub 2018 Aug 8.

PMID:
30089900
6.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN.

J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.

7.

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.

Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.

Lancet Haematol. 2018 Jan;5(1):e44-e52. doi: 10.1016/S2352-3026(17)30215-6. Epub 2017 Dec 14.

8.

Determination of l-glutamic acid and γ-aminobutyric acid in mouse brain tissue utilizing GC-MS/MS.

Farthing CA, Farthing DE, Gress RE, Sweet DH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:64-70. doi: 10.1016/j.jchromb.2017.10.020. Epub 2017 Oct 9.

PMID:
29031110
9.

Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.

Curtis LM, Pirsl F, Steinberg SM, Mitchell SA, Baird K, Cowen EW, Mays J, Buxbaum NP, Pichard DC, Im A, Avila D, Taylor T, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1980-1988. doi: 10.1016/j.bbmt.2017.08.005. Epub 2017 Aug 7.

10.

Comparing DNA enrichment of proliferating cells following administration of different stable isotopes of heavy water.

Farthing DE, Buxbaum NP, Lucas PJ, Maglakelidze N, Oliver B, Wang J, Hu K, Castro E, Bare CV, Gress RE.

Sci Rep. 2017 Jun 22;7(1):4043. doi: 10.1038/s41598-017-04404-2.

11.

In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease.

Buxbaum NP, Farthing DE, Maglakelidze N, Lizak M, Merkle H, Carpenter AC, Oliver BU, Kapoor V, Castro E, Swan GA, Dos Santos LM, Bouladoux NJ, Bare CV, Flomerfelt FA, Eckhaus MA, Telford WG, Belkaid Y, Bosselut RJ, Gress RE.

JCI Insight. 2017 Jun 15;2(12). pii: 92851. doi: 10.1172/jci.insight.92851. eCollection 2017 Jun 15.

12.

FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche.

Williams KM, Moore AR, Lucas PJ, Wang J, Bare CV, Gress RE.

Exp Hematol. 2017 Aug;52:40-49. doi: 10.1016/j.exphem.2017.05.005. Epub 2017 May 26.

13.

Systemic toxoplasma infection triggers a long-term defect in the generation and function of naive T lymphocytes.

Kugler DG, Flomerfelt FA, Costa DL, Laky K, Kamenyeva O, Mittelstadt PR, Gress RE, Rosshart SP, Rehermann B, Ashwell JD, Sher A, Jankovic D.

J Exp Med. 2016 Dec 12;213(13):3041-3056. Epub 2016 Nov 14.

14.

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, Yan XY, Rose J, Mays JW, Dhamala S, Kapoor V, Telford W, Dickinson J, Davis S, Halverson D, Naik HB, Baird K, Fowler D, Stroncek D, Cowen EW, Pavletic SZ, Gress RE.

J Immunol. 2016 Nov 1;197(9):3490-3503. Epub 2016 Sep 30.

15.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN.

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

16.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y, Gattinoni L.

Blood. 2016 Jul 28;128(4):519-28. doi: 10.1182/blood-2015-11-683847. Epub 2016 May 25.

17.

Distinct IL-7 signaling in recent thymic emigrants versus mature naïve T cells controls T-cell homeostasis.

Kim HK, Waickman AT, Castro E, Flomerfelt FA, Hawk NV, Kapoor V, Telford WG, Gress RE.

Eur J Immunol. 2016 Jul;46(7):1669-80. doi: 10.1002/eji.201546214. Epub 2016 May 17.

18.

Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.

Pirsl F, Curtis LM, Steinberg SM, Tella SH, Katić M, Dobbin M, Hsu J, Hakim FT, Mays JW, Im AP, Pulanić D, Mitchell SA, Baruffaldi J, Masuch L, Halverson DC, Gress RE, Barsony J, Pavletic SZ.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1517-1524. doi: 10.1016/j.bbmt.2016.04.012. Epub 2016 Apr 23.

19.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN.

J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.

20.

Analysis of Cell Proliferation and Homeostasis Using EdU Labeling.

Flomerfelt FA, Gress RE.

Methods Mol Biol. 2016;1323:211-20. doi: 10.1007/978-1-4939-2809-5_18.

PMID:
26294411
21.

Bone Marrow and Fetal Liver Radiation Chimeras.

Flomerfelt FA, Gress RE.

Methods Mol Biol. 2016;1323:109-15. doi: 10.1007/978-1-4939-2809-5_9.

PMID:
26294402
22.

Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

Curtis LM, Datiles MB 3rd, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW, Mays J, McCarty JM, Kuzmina Z, Pirsl F, Fowler DH, Gress RE, Pavletic SZ.

Haematologica. 2015 Sep;100(9):1228-36. doi: 10.3324/haematol.2015.124131. Epub 2015 Jun 18.

23.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH.

Clin Cancer Res. 2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.

24.

Oral disease profiles in chronic graft versus host disease.

Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Cowen EW, Naik H, Datiles M, Stratton P, Gress RE, Pavletic SZ.

J Dent Res. 2015 Apr;94(4):547-54. doi: 10.1177/0022034515570942. Epub 2015 Mar 4.

25.

Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo.

Amarnath S, Foley JE, Farthing DE, Gress RE, Laurence A, Eckhaus MA, Métais JY, Rose JJ, Hakim FT, Felizardo TC, Cheng AV, Robey PG, Stroncek DE, Sabatino M, Battiwalla M, Ito S, Fowler DH, Barrett AJ.

Stem Cells. 2015 Apr;33(4):1200-12. doi: 10.1002/stem.1934.

26.

NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.

Curtis LM, Grkovic L, Mitchell SA, Steinberg SM, Cowen EW, Datiles MB, Mays J, Bassim C, Joe G, Comis LE, Berger A, Avila D, Taylor T, Pulanic D, Cole K, Baruffaldi J, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Dec;49(12):1513-20. doi: 10.1038/bmt.2014.188. Epub 2014 Aug 25.

PMID:
25153693
27.

Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity.

Lee-Chang C, Bodogai M, Moritoh K, Olkhanud PB, Chan AC, Croft M, Mattison JA, Holst PJ, Gress RE, Ferrucci L, Hakim F, Biragyn A.

Blood. 2014 Aug 28;124(9):1450-9. doi: 10.1182/blood-2014-03-563940. Epub 2014 Jul 18.

28.

Malnutrition in patients with chronic GVHD.

Bassim CW, Fassil H, Dobbin M, Steinberg SM, Baird K, Cole K, Joe G, Comis LE, Mitchell SA, Grkovic L, Edwards D, Mays JW, Cowen EW, Pulanic D, Williams KM, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Oct;49(10):1300-6. doi: 10.1038/bmt.2014.145. Epub 2014 Jul 14.

29.

Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Imanguli MM, Cowen EW, Rose J, Dhamala S, Swaim W, Lafond S, Yagi B, Gress RE, Pavletic SZ, Hakim FT.

Leukemia. 2014 Oct;28(10):2016-27. doi: 10.1038/leu.2014.92. Epub 2014 Feb 28.

PMID:
24577531
30.

NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.

Williams KM, Hnatiuk O, Mitchell SA, Baird K, Gadalla SM, Steinberg SM, Shelhamer J, Carpenter A, Avila D, Taylor T, Grkovic L, Pulanic D, Comis LE, Blacklock-Schuver B, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Apr;49(4):561-6. doi: 10.1038/bmt.2013.222. Epub 2014 Jan 13.

31.

Thymic medullary epithelium and thymocyte self-tolerance require cooperation between CD28-CD80/86 and CD40-CD40L costimulatory pathways.

Williams JA, Zhang J, Jeon H, Nitta T, Ohigashi I, Klug D, Kruhlak MJ, Choudhury B, Sharrow SO, Granger L, Adams A, Eckhaus MA, Jenkinson SR, Richie ER, Gress RE, Takahama Y, Hodes RJ.

J Immunol. 2014 Jan 15;192(2):630-40. doi: 10.4049/jimmunol.1302550. Epub 2013 Dec 13.

32.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.

Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.

33.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.

Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1537-45. doi: 10.1016/j.bbmt.2013.08.010. Epub 2013 Sep 6.

34.

Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.

Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Cole K, Taylor T, Avila D, Zhang D, Pulanic D, Grkovic L, Fowler D, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Jan;49(1):116-21. doi: 10.1038/bmt.2013.137. Epub 2013 Sep 2.

35.

Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1509-13. doi: 10.1016/j.bbmt.2013.08.001. Epub 2013 Aug 13.

36.

Sensitive GC-MS/MS method to measure deuterium labeled deoxyadenosine in DNA from limited mouse cell populations.

Farthing DE, Buxbaum NP, Bare CV, Treadwell SM, Kapoor V, Williams KM, Gress RE.

Anal Chem. 2013 May 7;85(9):4613-20. doi: 10.1021/ac400309d. Epub 2013 Apr 10.

37.

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.

Blood. 2013 Apr 11;121(15):2864-74. doi: 10.1182/blood-2012-08-446872. Epub 2013 Feb 20.

38.

Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C, Biragyn A.

Cancer Res. 2013 Apr 1;73(7):2127-38. doi: 10.1158/0008-5472.CAN-12-4184. Epub 2013 Jan 30.

39.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.

Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.

40.

National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9. doi: 10.1016/j.bbmt.2013.01.013. Epub 2013 Jan 20.

41.

Oral chronic graft-vs.-host disease characterization using the NIH scale.

Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Taylor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, Pavletic SZ.

J Dent Res. 2012 Jul;91(7 Suppl):45S-51S.

42.

Health benefits of gastric bypass surgery after 6 years.

Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC.

JAMA. 2012 Sep 19;308(11):1122-31.

43.

High levels of IL-7 cause dysregulation of thymocyte development.

El-Kassar N, Flomerfelt FA, Choudhury B, Hugar LA, Chua KS, Kapoor V, Lucas PJ, Gress RE.

Int Immunol. 2012 Oct;24(10):661-71. Epub 2012 Aug 16.

44.

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.

Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR.

Bone Marrow Transplant. 2013 Feb;48(2):269-77. doi: 10.1038/bmt.2012.132. Epub 2012 Jul 9.

45.

An in vivo IL-7 requirement for peripheral Foxp3+ regulatory T cell homeostasis.

Kim GY, Ligons DL, Hong C, Luckey MA, Keller HR, Tai X, Lucas PJ, Gress RE, Park JH.

J Immunol. 2012 Jun 15;188(12):5859-66. doi: 10.4049/jimmunol.1102328. Epub 2012 May 16.

46.

No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.

Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, Horowitz MM, Ballen KK.

Transpl Infect Dis. 2012 Oct;14(5):468-78. doi: 10.1111/j.1399-3062.2012.00732.x. Epub 2012 May 1.

47.

Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.

J Clin Oncol. 2012 Mar 10;30(8):830-6. doi: 10.1200/JCO.2011.37.0296. Epub 2012 Feb 6. Erratum in: J Clin Oncol. 2012 May 1;30(13):1570. Dosage error in article text.

48.

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.

Blood. 2012 Mar 22;119(12):2956-9. doi: 10.1182/blood-2011-09-378398. Epub 2012 Jan 30.

49.

The aging immune system and its relationship with cancer.

Foster AD, Sivarapatna A, Gress RE.

Aging health. 2011 Oct 1;7(5):707-718.

50.

Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.

Leukemia. 2012 Apr;26(4):633-43. doi: 10.1038/leu.2011.254. Epub 2011 Oct 18.

Supplemental Content

Loading ...
Support Center